Short Interest in Surrozen, Inc. (NASDAQ:SRZN) Drops By 16.0%

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 42,400 shares, a decline of 16.0% from the April 30th total of 50,500 shares. Currently, 0.9% of the company's stock are sold short. Based on an average daily trading volume, of 11,900 shares, the days-to-cover ratio is currently 3.6 days.

Surrozen Stock Performance

Surrozen stock traded down $0.14 during midday trading on Friday, hitting $8.50. 1,167 shares of the company were exchanged, compared to its average volume of 20,898. The firm has a market capitalization of $72.79 million, a PE ratio of -0.34 and a beta of 0.57. Surrozen has a fifty-two week low of $5.90 and a fifty-two week high of $18.17. The business has a fifty day simple moving average of $9.09 and a two-hundred day simple moving average of $10.61.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($3.13) EPS for the quarter, missing the consensus estimate of ($1.09) by ($2.04). The company had revenue of $0.98 million during the quarter. As a group, equities analysts expect that Surrozen will post -8.49 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $32.00 price objective on shares of Surrozen in a report on Monday, May 12th.

Insider Buying and Selling

In other news, major shareholder Group Gp Lp Column III acquired 1,034,482 shares of the business's stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $11.60 per share, with a total value of $11,999,991.20. Following the completion of the acquisition, the insider now owns 795,411 shares of the company's stock, valued at approximately $9,226,767.60. This trade represents a -432.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 45.18% of the stock is owned by company insiders.

Institutional Trading of Surrozen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. grew its holdings in Surrozen by 140.3% during the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after acquiring an additional 396,550 shares during the period. Stempoint Capital LP boosted its position in Surrozen by 91.7% during the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company's stock worth $5,031,000 after purchasing an additional 167,655 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in Surrozen in the first quarter valued at approximately $3,615,000. Stonepine Capital Management LLC grew its holdings in Surrozen by 108.3% in the first quarter. Stonepine Capital Management LLC now owns 285,782 shares of the company's stock valued at $3,332,000 after purchasing an additional 148,582 shares during the period. Finally, Vivo Capital LLC acquired a new stake in Surrozen in the first quarter valued at approximately $3,032,000. 66.57% of the stock is owned by institutional investors and hedge funds.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.